The Swiss rare diseases firm Santhera has signed a licensing deal for its Duchenne muscular dystrophy drug vamorolone, which could be launched in both the US and the EU by the end of the year, paying off short-term debt and cleaning up the balance sheet.
With regulatory decisions imminent on both sides of the Atlantic for vamorolone, Santhera Pharmaceuticals has secured a North America partner for the closely watched Duchenne muscular dystrophy (DMD) therapy while banking a healthy upfront payment.
The Swiss group has signed a license and collaboration agreement for vamorolone with Catalyst Pharmaceuticals, Inc. covering the US,...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
But the French major is still keen on early-stage M&A.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
